Olga B. H.
- Country
- Spain
- Department
- N/A
Research Overview
- A phase 3b open-label, multicenter study evaluating physical activity and joint health in previously treated patients ≥12 years of age with severe haemophilia A treated with intravenous recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; efanesoctocog alfa) for 24 months
- Phase 1 Open‑Label Dose‑Escalation Study of Inno8 in Adults and Adolescents with Haemophilia A, With or Without Inhibitors, Assessing Pharmacokinetics and Safety
- Phase III Randomized Open‑Label Trial of Subcutaneous NXT007 Prophylaxis versus Intravenous Factor VIII Prophylaxis in Patients with Hemophilia A without Inhibitors
Data & Insights
Has run more than one trial at 46 of 96 partner sites.
Specializations
Hemophilia A Research
The investigator specializes in studying severe hemophilia A treatment approaches, with particular focus on evaluating novel therapeutic agents like efanesoctocog alfa and emicizumab. Their research encompasses assessment of physical activity patterns and joint health outcomes in patients receiving prophylactic treatments.
- Joint Health Assessment
- Physical Activity Monitoring
- Synovial Hypertrophy Management
Additional interests include investigating gene therapy approaches for hemophilia A treatment and studying FVIII inhibitor management strategies.
Hemophilia B Studies
The investigator conducts research in moderately severe to severe hemophilia B, focusing on innovative treatments including gene therapy solutions and novel therapeutic agents. Their work includes evaluation of Factor IX gene therapy and emerging treatment modalities.
- Gene Therapy Assessment
- Clotting Factor Production
- Bleeding Episode Prevention
The research extends to studying both prophylactic treatments and breakthrough therapeutic approaches for hemophilia B management.
Complex Coagulation Disorders
The investigator's expertise extends to various complex bleeding disorders, including von Willebrand Disease and hemophilia with inhibitors. Their research focuses on developing comprehensive treatment strategies for patients with challenging coagulation conditions.
- Inhibitor Management
- Prophylactic Treatment Evaluation
- Quality of Life Assessment
Research activities include investigation of novel prophylactic approaches and assessment of bleeding prevention strategies in pediatric and adult populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.